No tax




Security policy (edit with Customer reassurance module)


Delivery policy (edit with Customer reassurance module)


Return policy (edit with Customer reassurance module)


Nasal spray

1 ml

active substances:

xylometazoline hydrochloride

0.5 mg

ipratropium bromide monohydrate

0.6 mg

Excipients: glycerol (85%) - 27.9 mg; disodium edetate dihydrate - 0.5 mg; concentrated hydrochloric acid or sodium hydroxide - q.s. up to pH 4.5; water - up to 1 ml

Description of the dosage form

Transparent colorless or slightly colored solution with almost no odor.


pharmachologic effect - anticholinergic, alpha adrenomimetic, anti-congestive.


Xylometazoline It belongs to the group of local vasoconstrictor agents (decongestants) with α-adrenomimetic action, causes constriction of the blood vessels of the nasal mucosa, thus eliminating the swelling and hyperemia of the nasopharyngeal mucosa. Relieves nasal congestion, facilitating nasal breathing with rhinitis.

Ipratropium bromide has anticholinergic effect. With intranasal use, it reduces nasal secretion, stopping hypersecretion of the glands of the nasal mucosa due to competitive inhibition of cholinergic receptors located in the epithelium of the nasal cavity. In therapeutic concentrations does not irritate the mucous membrane, does not cause its hyperemia.

The drug begins to act after 5-10 minutes and has a lasting effect for 6-8 hours.


With intranasal administration, ipratropium bromide and xylometazoline hydrochloride are little absorbed and are present in plasma in small quantities.

Indications drug Otrivin ® Complex

symptomatic treatment of edema and hyperemia of the nasal cavity;

acute respiratory infections with rhinitis (rhinitis), accompanied by congestion;

acute allergic rhinitis;




hypersensitivity to the drug;

hypersensitivity to atropine or similar compounds (hyoscyamine, scopolamine);


surgical interventions on the membranes of the brain (in history);

pregnancy (I term);

atrophic rhinitis;

age up to 18 years.

Carefully: diabetes; hyperthyroidism; pheochromocytoma; angina of the III – IV functional class; bladder neck obstruction; prostatic hyperplasia. It is recommended to be careful in treating patients prone to nasal bleeding, dizziness, skeletal muscle tremor, sleep disorders, arrhythmias, increased blood pressure, intestinal paralytic obstruction and patients with cystic fibrosis.

If the patient has one of the listed diseases, you should always consult with your doctor before taking the drug.

Pregnanacy and breastfeeding

During pregnancy (II – III trimesters) and breastfeeding, the drug should be used only after a careful assessment of the benefit-risk ratio for the mother and the fetus; the recommended dosage is not allowed to exceed.

Adverse effects

The classification of the frequency of adverse reactions: very often - more than 1/10 of appointments (≥10%); often more than 1/100, but less than 1/10 of appointments (≥1%, but <10%); infrequently - more than 1/1000, but less than 1/100 of appointments (≥0.1%, but <1%); rarely, more than 1/10000, but less than 1/1000 appointments (≥0.01%, but <0.1%); very rarely - less than 1/10000 appointments (<0.01%).

Nervous system: often - headache; rarely - dizziness; very rarely - insomnia.

Gastrointestinal: often - dry mouth; infrequently - dyspepsia, nausea.

Special senses: rarely - increased IOP, mydriasis, eye pain, deterioration in angle-closure glaucoma; very rarely - a violation of the clarity of visual perception.

Urogenital: rarely, difficulty urinating.

Respiratory: often - nosebleeds, irritation and / or dryness of the mucous membrane of the nasopharynx, burning sensation, tingling, sneezing, nasal hypersecretion; infrequently - nasal congestion (with frequent and / or long-term use of the drug).

From the CCC: rarely - rapid heartbeat, supraventricular tachycardia, atrial fibrillation; very rarely - arrhythmic pulse.

From the skin: rarely - itching, skin rash, urticaria.

Allergic reactions: rarely, systemic allergic reactions (anaphylactic reaction, angioedema of the tongue, lips and face, laryngospasm).

If any of the above side effects are exacerbated or any other side effects that are not listed in the description are noticed, you should inform your doctor.


The drug is incompatible with MAO inhibitors, tri- and tetracyclic antidepressants.

Sympathomimetic drugs cause the release of catecholamines, incl. norepinephrine, which has a vasoconstrictor effect, resulting in increased blood pressure. With a significant increase in blood pressure treatment drug Otrivin® The complex should be abolished, symptomatic treatment.

Simultaneous use with tri- and tetracyclic antidepressants can enhance the sympathomimetic effect of xylometazoline.

With the concomitant prescription of other drugs with anticholinergic activity, it is possible to enhance the anticholinergic effect of ipratropium bromide.

Dosage and administration


For patients over the age of 18, take 1 injection in each nasal passage 3 times a day. The drug is used for no more than 7 days without consulting a doctor. Prolonged use of Xylometazoline may cause swelling of the nasal mucosa and increased secretion, due to the development of increased sensitivity of cells to the active ingredients of the drug, the so-called. the opposite effect.

One injection of the drug Otrivin® The complex contains about 70 mcg xylometazoline hydrochloride and 84 mcg ipratropium bromide.


When nasal use of the drug Otrivin® The complex acute overdose is unlikely, since drug absorption is extremely low.


Symptoms: the clinical picture is characterized by nausea, sweating, lowering of body temperature, headache, bradycardia, accommodation disturbance, arterial hypertension, respiratory depression, coma. Hypertension can be replaced by hypotension.

Treatment: symptomatic therapy should be carried out under medical supervision.

Ipratropium bromide

Symptoms: with excessive use of ipratropium bromide overdose is unlikely, due to the extremely low absorption of the substance into the blood, but dry mouth, difficulty in accommodation, tachycardia can develop.

Treatment: symptomatic.

Significant overdose can cause symptoms associated with the anticholinergic effect of the drug on the part of the central nervous system, including hallucinations, to eliminate which cholinesterase inhibitors are prescribed.

Special notes

Before use, you must clean the nasal passages.

It should not be used for a long time, such as chronic rhinitis.

Do not allow the drug to get into or around the eyes. In case of contact, there may be temporary blurred vision, irritation, pain, redness of the eyes, possibly the development of acute angle-closure glaucoma.It should be abundantly flush eyes with cold water in case of contact with the drug and consult a doctor if you have pain in the eyes or blurred vision.

Influence on ability to drive vehicles and mechanisms. Use of the drug Otrivin® The complex in therapeutic doses does not affect the ability to drive vehicles and mechanisms.

Release form

Spray nasal, 0.5 mg / ml + 0.6 mg / ml. On 10 ml of a preparation in the bottle from PVP supplied with the pump dosing device with a tip from polypropylene and a protective cap from PE. The bottle is placed in a cardboard box.

Storage conditions of the drug Otrivin® Complex

At temperatures not above 25 ° C.

Keep out of the reach of children.

38 Items